ClinicalTrials.gg
Active, not recruitingNCT06001385OPTIMIZEUpdated Aug 17, 2026

HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis

A Phase 2 interventional study of Busulfan and Fludarabine in Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia and Acute Leukemia, sponsored by Center for International Blood and Marrow Transplant Research. Active, not recruiting at 32 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-08-17.

Sponsored by Center for International Blood and Marrow Transplant Research · Phase 2, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
313
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma — 7 open to participants now, 13 under way, 1 of them phase 3. Busulfan · Precursor Cell Lymphoblastic Leukemia-Lymphoma.

Planned enrollment
5th of 71
313 · median 40
Started
2023
with 1 other
Phase 2
48 of 73
6 open now
Primary completion
2026-12
later than 4 of 12 live
Registered
72nd of 73
by date
Lead sponsor
3 of 73
Center for International Blood and Marrow Transplant Research

Among the 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma, this one is the 5th largest by planned enrollment of the 71 interventional ones that give a count, is one of 2 that started in 2023, is one of 48 in phase 2, reaches primary completion later than 4 of the 12 other live ones, and was the 72nd registered.

Precursor Cell Lymphoblastic Leukemia-Lymphoma

2,586 studies on the registry are indexed under Precursor Cell Lymphoblastic Leukemia-Lymphoma; 471 are open to participants now.

Browse Precursor Cell Lymphoblastic Leukemia-Lymphoma studies →

Open to participants now

7 of the 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma are open now, in 12 countries. Recruiting first, the newest first:

2 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About busulfan

Busulfan: first FDA approval 1954 (MYLERAN), first EMA approval 2003. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 369 Precursor Cell Lymphoblastic Leukemia-Lymphoma studies recruiting now, 96 (26%) set no upper age limit and 257 (70%) stop at 75 or younger; 247 take children under 18; 29 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 73 studies testing busulfan in Precursor Cell Lymphoblastic Leukemia-Lymphoma, or all of them as a file.
02

Study summary

The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are:

  • Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant?
  • Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose of PTCy?
03

Conditions studied

  • Acute Lymphoblastic Leukemia
  • Acute Myeloid Leukemia
  • Acute Leukemia
  • Myelodysplastic Syndromes
  • Chronic Myeloid Leukemia
  • Chronic Lymphocytic Leukemia
  • Myeloproliferative Neoplasm
  • Lymphoma
  • Chronic Myelomonocytic Leukemia
  • Pro-Lymphocytic Leukemia
  • Myelofibrosis

Keywords

  • Lymphoma
  • Leukemia
  • Hematologic Diseases
  • Myelodysplastic Syndromes
  • Preleukemia
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • Leukemia , Lymphocytic, Chronic, B-Cell
  • Leukemia, Myeloid, Acute
  • Leukemia, Biphenotypic, Acute
  • Neoplasms by Histologic Type
  • Neoplasms
  • Lymphoproliferative Disorders
  • Lymphatic Diseases
  • Immunoproliferative Disorders
  • Immune System Disorders
  • Bone Marrow Diseases
  • Precancerous Conditions
  • Leukemia, Lymphoid
  • Leukemia, B-Cell
  • Leukemia, Myeloid
  • Cyclophosphamide
  • Mesna
  • Tacrolimus
  • Busulfan
  • Fludarabine
  • Total Body Irradiation
  • Melphalan
  • Mycophenolate mofetil
  • Reduced Dose Cyclophosphamide
  • Immunosuppressive Agents
  • Immunologic Factors
  • Physiological Effects of Drugs
  • Hematopoietic Stem Cell Transplantation
  • Peripheral Blood Stem Cells
  • Unrelated Donors
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Stratum 1 Recipient Inclusion Criteria:

  1. Age ≥ 18 years and \< 66 years (chemotherapy-based conditioning) or \< 61 years (total body irradiation [TBI]-based conditioning) at the time of signing
  2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and institutional requirements.
  3. Stated willingness to comply with all study procedures and availability for the duration of the study.
  4. Planned MAC regimen as defined per study protocol
  5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred).
  6. Product planned for infusion is MMUD T-cell replete PBSC allograft
  7. HCT-CI \< 5. The presence of prior will not be used to calculate HCT-CI for this trial to allow for the inclusion of patients with secondary or therapy-related AML or MDS.
  8. One of the following diagnoses:

    1. Acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or other acute leukemia in 1st remission or beyond with ≤ 5% marrow blasts and no circulating blasts or evidence of extra-medullary disease. Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
    2. Patients with MDS with no circulating blasts and with \< 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \< 5% or 5-10% blasts in MDS). Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
  9. Cardiac function: ≥ 45% based on most recent echocardiogram or multi-gated acquisition scan (MUGA) results.
  10. Estimated ≥ 45mL/min calculated by equation.
  11. Pulmonary function: diffusing capacity of the lungs for carbon monoxide (DLCO) corrected for > 50% and forced expiratory volume in first second () predicted > 50% based on most recent pulmonary function test (PFT) results
  12. Liver function acceptable per local institutional guidelines
  13. of ≥ 70%

Stratum 2 Recipient Inclusion Criteria:

  1. Age ≥18 years at the time of signing informed consent
  2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements.
  3. Stated willingness to comply with all study procedures and availability for the duration of the study.
  4. Planned NMA/RIC regimen per study protocol
  5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred).
  6. Product planned for infusion is MMUD T-cell replete PBSC allograft
  7. One of the following diagnoses:

    1. Patients with acute leukemia or chronic myeloid leukemia (CML) with no circulating blasts, no evidence of extramedullary disease, and with \< 5% blasts in the bone marrow.

      Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.

    2. Patients with MDS with no circulating blasts and with \< 10% blasts in the bone marrow (higher blast percentage allowed in MDS due to lack of differences in outcomes with \< 5% or 5-10% blasts in MDS.) Documentation of bone marrow assessment will be accepted within 45 days prior to the anticipated start of conditioning.
    3. Patients with chronic lymphocytic leukemia (CLL) or other leukemias (including prolymphocytic leukemia) with chemosensitive disease at time of transplantation
    4. Higher risk CMML according to CMML-specific prognostic scoring system or high risk MDS/MPN not otherwise specified are eligible, provided there is no evidence of high-grade bone marrow fibrosis or massive splenomegaly at the time of enrollment.
    5. Patients with lymphoma with chemosensitive disease at the time of transplantation
  8. Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure
  9. Estimated creatinine clearance ≥ 45mL/min calculated by equation
  10. Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted >50% based on most recent PFT results
  11. Liver function acceptable per local institutional guidelines
  12. KPS of ≥ 60%

Stratum 3 Recipient Inclusion Criteria:

  1. Age ≥18 years at the time of signing informed consent
  2. Patient or legally authorized representative has the ability to provide informed consent according to the applicable regulatory and local institutional requirements.
  3. Stated willingness to comply with all study procedures and availability for the duration of the study.
  4. Planned NMA/RIC regimen per study protocol
  5. Available partially HLA-MMUD (4/8-7/8 at HLA-A, -B, -C, and -DRB1 is required) with age ≥ 18 and ≤ 40 years (≤ 35 preferred).
  6. Product planned for infusion is MMUD T-cell replete PBSC allograft
  7. Diagnosis of primary myelofibrosis with risk features making them eligible for HCT. Myelofibrosis secondary to essential thrombocythemia, polycythemia vera, or MDS with grade 4 fibrosis are also eligible. Patients with a myelofibrosis diagnosis require sponsor approval before enrolling.
  8. Cardiac function: Left ventricular ejection fraction ≥ 40% based on most recent echocardiogram or MUGA results with no clinical evidence of heart failure
  9. Estimated creatinine clearance ≥ 45 mL/min calculated by equation
  10. Pulmonary function: DLCO corrected for hemoglobin > 50% and FEV1 predicted >50% based on most recent PFT results
  11. Liver function acceptable per local institutional guidelines
  12. KPS of ≥ 60%

Donor Inclusion Criteria (note: donors are not research subjects):

  1. Must be unrelated to the subject and high-resolution HLA-matched at 4/8, 5/8, 6/8, or 7/8 (HLA-A, -B, -C, and -DRB1.
  2. Donor must be typed at high-resolution for a minimum of HLA-A, -B, -C, -DQB1, and -DPB1.
  3. Age ≥ 18 years and ≤ 40 years at the time of signing informed consent for PBSC donation. Note: donors are preferred to be ≤ 35.
  4. Meet the donor registries' medical suitability requirements for PBSC donation.
  5. Must undergo eligibility screening according to current Food and Drug Administration (FDA) requirements. Donors who do not meet one or more of the donor screening requirements may donate under urgent medical need.
  6. Must agree to donate PBSC.
  7. Must have the ability to give informed consent according to standard (non-study) informed consent according to applicable donor regulatory requirements.

Recipient Exclusion Criteria (Strata 1, 2, and 3):

  1. Suitable HLA-matched related or 8/8 high-resolution matched unrelated donor available
  2. Subject unwilling or unable to give informed consent, or unable to comply with the protocol including required follow-up and testing
  3. Subjects with a prior transplant
  4. Subjects with an autologous transplant within the past 3 months
  5. Females who are breast-feeding or pregnant
  6. Uncontrolled bacterial, viral, or fungal infection at the time of the transplant preparative regimen
  7. Concurrent enrollment on a preventative GvHD and/or infectious disease prevention clinical trial.
  8. Subjects who undergo desensitization to reduce anti-donor HLA antibody levels prior to transplant.
  9. Patients who are + with persistently positive viral load. HIV-infected patients on effective anti-retroviral therapy (ART) with undetectable viral load within 6 months are eligible for this trial. Patients with well controlled HIV are eligible provided resistance panels are negative, the patient is compliant with ART, and their disease remains well controlled.

Donor Exclusion Criteria:

  1. Donor unwilling or unable to donate.
  2. Recipient positive for HLA antibodies against a mismatched HLA in the selected donor determined by the presence of donor specific HLA antibodies (DSA) to any mismatched HLA allele/antigen at any of the following loci (HLA-A, -B, -C, -DRB1, DRB3, DRB4, DRB5, -DQA1, - DQB1, -DPA1, -DPB1) with median fluorescence intensity (MFI) >3000 by microarray-based single antigen bead testing. In patients receiving red blood cell or transfusions, DSA evaluation must be performed or repeated post-transfusion and prior to donor mobilization and initiation of recipient preparative regimen.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
313 participants (estimated)

Study arms

  • Experimental
    Regimen A (MAC: Busulfan and Fludarabine, PBSC HCT; Reduce Dose PTCy

    Patients Receive: Patients receive: Busulfan (≥ 9 mg/kg total dose) IV or PO on days -6 to -3 Fludarabine (150 mg/m2 total dose) IV on days -6 to -2 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.

    Drug: Busulfan · Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes

  • Experimental
    Regimen B (MAC: Fludarabine and TBI, PBSC HCT; Reduce Dose PTCy

    Patients receive: Fludarabine (90 mg/m2 total dose) IV on days -7 to -5 Total body irradiation (TBI) (1200 cGy total dose) on days -4 to -1 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.

    Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Radiation: Total-body irradiation

  • Experimental
    Regimen C (RIC: Fludarabine and Busulfan; PBSCT HCT; Reduced Dose PTCy

    Patients receive: Fludarabine (150-180 mg/m2 total dose) IV on days -6 to -2 Busulfan (less than or equal to 8 mg/kg PO or 6.4 mg/kg IV) on days -5 and -4 Patients receive a peripheral blood stem cell (PBSC) graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.

    Drug: Busulfan · Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes

  • Experimental
    Regimen D (RIC: Fludarabine and Melphalan; PBSCT HCT; Reduced Dose PTCy

    Patients receive: Fludarabine (125-150 mg/m2 total dose) IV on days -7 to -3 Melphalan (100-140 mg/m2) IV on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.

    Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Drug: Melphalan

  • Experimental
    Regimen E (NMA: Fludarabine, Cyclophosphamide, and TBI; PBSCT HCT; Reduced Dose PTCy

    Patients receive: Fludarabine (150mg/m2 total dose) IV on days -6 to -2 Cyclophosphamide (29-50mg/kg) IV on days -6 and -5 TBI (200cGy) on day -1 Patients receive a PBSC graft infusion from a mismatched unrelated donor on Day 0. Patients receive a reduced dose of cyclophosphamide (25mg/kg per dose) on Day 3 and Day 4 post-transplant. First 20 patients with a 4-6/8 mismatched unrelated donor will receive an alternate dose of post-transplant cyclophosphamide of 37.5 mg/kg on Days 3 and Day 4 post-transplant.

    Drug: Fludarabine · Procedure: PBSC Hematopoietic Stem Cell Transplantation (HSCT) · Drug: Post-Transplant Cyclophosphamide · Drug: Mesna · Drug: Tacrolimus · Drug: Mycophenolate Mofetil · Other: Patient Reported Outcomes · Radiation: Total-body irradiation · Drug: Cyclophosphamide

Interventions

  • Given IV or PO pre-transplant as part of conditioning regimen

    Also known as: Busulfex®

  • Given IV pre-transplant as part of conditioning regimen

    Also known as: Fludara®

  • ProcedurePBSC Hematopoietic Stem Cell Transplantation (HSCT)

    Peripheral blood stem cell graft is infused from a mismatched unrelated donor on Day 0

    Also known as: PBSC HSCT, PBSC HCT, PBSC Transplantation, PBSCT

  • DrugCyclophosphamideStudies of CyclophosphamideCyclophosphamide pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Cyclophosphamide (25mg/kg) is administered on Day 3 and Day 4 post-transplant as an IV infusion over 1-2 hours. First 20 subjects with a 4-6/8 HLA mismatched unrelated donor will receive an intermediate dose of post-transplant cyclophosphamide of 37.5 mg/kg Day 3 and Day 4 post-transplant.

    Also known as: Cytoxan®, PTCy

  • DrugMesna

    Mesna is given in divided doses IV 30 min pre- and at 3, 6, and 8 hours post cyclophosphamide.

    Also known as: Mesnex®

  • Tacrolimus is given at a dose of 0.05 mg/kg PO or an IV dose of 0.03 mg/kg of ideal body weight (IBW) starting on Day +5 post-transplant with taper recommended at Day + 90 and finished by Day +180.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Mycophenolate mofetil (MMF) is given at a dose of 15 mg/kg three times daily IV or PO from Day +5 to Day +35 post-transplant.

    Also known as: MMF, Cellcept®

  • OtherPatient Reported Outcomes

    Survey assessments will be administered to study participants pre transplant, at Day + 100, Day + 180, and Day +365 post transplant.

    Also known as: PRO

  • Given IV pre transplant as part of conditioning regimen

  • RadiationTotal-body irradiation

    Administered pre-transplant as part of conditioning regimen

    Also known as: TBI

  • Given IV pre-transplant as part of conditioning regimen

    Also known as: Cytoxan®

06

What researchers measure

Primary outcomes

  1. Infection Free Survival

    Survival at 100 days without grades 2-3 infections (per BMT CTN grading criteria)

    Time frame: 100 days post-HCT

Secondary outcomes

  1. Overall Survival

    Defined as time interval between date of transplant and death from any cause

    Time frame: 1-year post-HCT

  2. Progression-free survival

    Defined as disease relapse or progression, or death by any cause

    Time frame: 1-year post-HCT

  3. Infection-free survival

    Defined as death and grades II-III infection (per BMT CTN criteria)

    Time frame: 1-year post-HCT

  4. Graft versus host disease relapse free survival

    Defined as relapse or progression of underling disease (by 1 year), grade III-IV acute GvHD (by 6 months), chronic GvHD requiring systemic immune suppression (by 1 year), or death by any cause (by 1 year).

    Time frame: 1-year post-HCT

  5. Non-relapse mortality

    Defined as death without evidence of disease progression or recurrence

    Time frame: 1-year post-HCT

  6. Cumulative incidence of neutrophil recovery

    Defined as achieving an absolute neutrophil count (ANC) greater than or equal to 500/mm3 for three consecutive measurements on three different days

    Time frame: Day 28 post-HCT

  7. Cumulative incidence of platelet recovery

    Defined as platelet count ≥20,000/mm\^3 or ≥50,000/mm\^3 with no platelet transfusions within seven days.

    Time frame: Day 28 post-HCT

  8. Cumulative incidence of primary and secondary graft failure

    Primary graft failure is defined as no neutrophil recovery to ≥ 500 cells/mm3 by Day 28 post HCT. Secondary graft failure is defined as as initial neutrophil count recovery followed by subsequent decline in absolute neutrophil counts \<500 cells/mm3, unresponsive to growth factor therapy, but cannot be explained by infection, disease relapse, or medications.

    Time frame: Day 28 and 1-year post-HCT

  9. Donor T-Cell Chimerism

    Defined as percent of donor chimerism via peripheral blood

    Time frame: Day 28, 100 and 365 post-HCT

  10. Cumulative incidence of acute GvHD

    Defined as cumulative incidence of grades II-IV acute GvHD

    Time frame: Day 100 and Day 180 post-HCT

  11. Cumulative incidence of chronic GvHD

    Time frame: 1-year post-HCT

  12. Cumulative incidence of grade 2-3 bacterial, fungal, and viral infections

    Defined as grades 2-3 infection as defined by BMT CTN grading criteria.

    Time frame: Day 100 and 1-year post-HCT

  13. Cumulative incidence of grades 2-3 BK virus hemorrhagic cystitis

    Defined as incidence of BK virus hemorrhagic cystitis per BMT CTN grading criteria

    Time frame: 1-year post-HCT

  14. Cumulative incidence of relapse/progression

    Defined as disease relapse or progression from Day 0 to 1-year post-HCT

    Time frame: 1-year post-HCT

  15. Overall Toxicity

    To tabulate adverse events (AEs, experienced by recipients, defined as grade 3-5 unexpected and grade 5 expected AEs according to CTCAE v5

    Time frame: 1-year post-HCT

  16. Incidence and Severity of cytokine release syndrome

    Defined and graded using the ASTCT grading criteria.

    Time frame: within 14 days post-HCT

07

Study locations

32 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2023 (actual). Primary completion is estimated for Dec 2026, 36 months after the start.

Of 209 non-industry phase 2 interventional studies under Precursor Cell Lymphoblastic Leukemia-Lymphoma, half reached primary completion within 79 months of starting (the median), counting those still running; a quarter within 42 and three quarters within 120. This study's planned 36 months is below that.

Counting every sponsor, half of 227 studies reached it within 74 months; a quarter within 42 and three quarters within 120.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 14, 2023
First posted
Aug 21, 2023
StartActual
Dec 8, 2023
Primary completionEst.
Dec 24, 2026
CompletionEst.
Dec 30, 2026
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06001385
Lead sponsor
Center for International Blood and Marrow Transplant Research
Collaborators
National Marrow Donor Program
Responsible party
Sponsor
First posted
Aug 21, 2023
Start date
Dec 8, 2023
Primary completion
Dec 24, 2026 (estimated)
Completion
Dec 30, 2026 (estimated)
Last update
Aug 17, 2026

Study contacts

Steven Devine, MD
principal investigator · NMDP
Ginna Laport, MD
study chair · NMDP

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Busulfan · Melphalan · Cyclophosphamide

Start the discussion